Subject:
- Active Substance: Sacituzumab Govitecan
- Name: Trodelvy®
- Therapeutic area: Breast cancer
- Pharmaceutical company: Gilead Sciences GmbH
Time table:
- Start: 01.12.2021
- Final decision by G-BA: 19.05.2022
Final decision:
- Indication for a major additional benefit